NGM Bio Announces Oral Plenary Presentation of Data from Phase 2b ALPINE 4 Trial of Aldafermin in Compensated Cirrhosis (F4) Due to NASH at Upcoming AASLD The Liver Meeting®
October 11, 2023 16:05 ET
|
NGM Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights
August 03, 2023 16:01 ET
|
NGM Biopharmaceuticals, Inc.
--Announced positive data from Phase 2 investigator-sponsored trial of aldafermin for the treatment of patients with diarrhea-predominant irritable bowel syndrome (IBS-D) and bile acid malabsorption...
NGM Bio to Participate in Upcoming Investor Conferences
May 25, 2023 09:00 ET
|
NGM Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Bile Acid Malabsorption (BAM) at Digestive Disease Week 2023
May 08, 2023 16:05 ET
|
NGM Biopharmaceuticals, Inc.
Aldafermin demonstrated statistically significant reductions in serum 7αC4 (a marker of bile acid synthesis) and fecal bile acids versus placebo in patients with idiopathic BAM with IBS-DAround 25-50%...
NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data
May 04, 2023 16:05 ET
|
NGM Biopharmaceuticals, Inc.
Phase 2b ALPINE 4 trial met its primary endpoint, demonstrating a statistically significant improvement in Enhanced Liver Fibrosis (ELF) score at 48 weeks versus baseline in patients with compensated...
NGM Bio to Participate in the Cowen 43rd Annual Health Care Conference
March 01, 2023 09:00 ET
|
NGM Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results
February 28, 2023 16:05 ET
|
NGM Biopharmaceuticals, Inc.
--Presented preliminary findings from the Phase 1a monotherapy dose escalation portion of the ongoing Phase 1/2 trial of NGM707 in patients with advanced or metastatic solid tumors at the ESMO I-O...
NGM Bio to Participate in the B. Riley Securities 3rd Annual Oncology Conference
January 12, 2023 08:00 ET
|
NGM Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities
January 09, 2023 09:00 ET
|
NGM Biopharmaceuticals, Inc.
NGM Bio’s three-pronged corporate strategy includes the following components: Focus internal clinical development efforts on solid tumor oncology portfolioGenerate next-generation biologics through...
NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual Meeting
December 12, 2022 19:00 ET
|
NGM Biopharmaceuticals, Inc.
--NGM936, a ILT3 x CD3 bispecific T cell engager product candidate, potently induced T cell dependent cytotoxicity (TDCC) against ILT3+ AML cells while inducing minimal cytokine release in preclinical...